We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

14 hedge funds and large institutions have $1.68M invested in Akari Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

27% more funds holding

Funds holding: 11 → 14 (+3)

0% more ownership

Funds ownership: 0% → 0% (+0%)

11% less capital invested

Capital invested by funds: $1.89M → $1.68M (-$210K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
+$92.2K
2
TSS
Two Sigma Securities
New York
+$36.4K
3
Citadel Advisors
Citadel Advisors
Florida
+$16.8K
4
Millennium Management
Millennium Management
New York
+$16K
5
UBS Group
UBS Group
Switzerland
+$3.55K

Top Sellers

Rank Fund Capital Flow
1
CAN
Cetera Advisor Networks
California
-$25K
2
VF
Virtu Financial
New York
-$20K
3
Morgan Stanley
Morgan Stanley
New York
-$7K
4
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$887
5
Renaissance Technologies
Renaissance Technologies
New York
-$887
Name Holding Trade Value Shares
Change 		Change in
Stake
OFW
1
Omnia Family Wealth
Florida
$758K – – –
NMC
2
NEA Management Company
Maryland
$452K – – –
HP
3
Hikari Power
Japan
$131K – – –
BMCM
4
Bryn Mawr Capital Management
Pennsylvania
$100K – – –
LPL Financial
5
LPL Financial
California
$83K +$92.2K +104 New
Renaissance Technologies
6
Renaissance Technologies
New York
$46K -$887 -1 -2%
TSS
7
Two Sigma Securities
New York
$33K +$36.4K +41 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$30K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$15K +$16.8K +19 New
Millennium Management
10
Millennium Management
New York
$14K +$16K +18 New
PNC Financial Services Group
11
PNC Financial Services Group
Pennsylvania
$12K -$887 -1 -7%
Bank of America
12
Bank of America
North Carolina
$3K – – –
UBS Group
13
UBS Group
Switzerland
$3K +$3.55K +4 New
TC
14
Truvestments Capital
Florida
$2K +$1.77K +2 New
CAN
15
Cetera Advisor Networks
California
– -$25K -26 Closed
VF
16
Virtu Financial
New York
– -$20K -21 Closed
Morgan Stanley
17
Morgan Stanley
New York
– -$7K -7 Closed

AKTX Hedge Fund Activity: Q2 2022 in Review

14 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2022, worth a combined $1.68M — down 11% from $1.89M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AKTX positions and 3 closed out — a net gain of 3 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was LPL Financial, opening a new position worth an estimated $92.2K. The largest seller was Cetera Advisor Networks, exiting entirely with an estimated $25K sold.

  • 14 institutional investors held Akari Therapeutics (AKTX) as of Q2 2022, up from 11 in Q1 2022.
  • Funds reported $1.68M of Akari Therapeutics stock for Q2 2022, down 11% quarter-over-quarter.
  • 6 funds opened new Akari Therapeutics positions in Q2 2022 and 3 closed out, a net change of +3 holders.
  • The largest Akari Therapeutics buyer in Q2 2022 was LPL Financial, an estimated $92.2K added.
  • The largest Akari Therapeutics seller in Q2 2022 was Cetera Advisor Networks, an estimated $25K sold.

Based on aggregated 13F filings for Q2 2022.